SCAP and hypertriglyceridemia: ENOblock treatment disrupted Srebp expression without increasing expression of the LXR target genes, Scap and Abcg5, which may cause hepatic steatosis and hypertriglyceridemia when Srebp expression is inhibited by pharmacological ligands40 (Fig. 6F).